论文部分内容阅读
目的分析胃癌实施新辅助化疗的效果。方法以我院收治的70例胃癌患者作为研究对象,随机分为两个组别,每组各35例。对照组实施手术+术后辅助化疗方案,试验组术前采用新辅助化疗方案,观察临床疗效,比较不良反应和复发情况。结果试验组治疗有效31例(88.6%),术后1年复发2例(5.7%);对照组治疗有效22例(62.9%),术后复发8例(22.9%),差异有统计学意义,P<0.05。两组患者的不良反应发生率分别为37.1%和45.7%,差异无统计学意义,P>0.05。结论胃癌患者在临床治疗期间,术前实施新辅助化疗效果显著,有利于控制肿瘤进展、减少复发情况,值得临床推广。
Objective To analyze the effect of neoadjuvant chemotherapy in gastric cancer. Methods 70 cases of gastric cancer admitted to our hospital as a research object, were randomly divided into two groups, 35 cases in each group. In the control group, operation and postoperative adjuvant chemotherapy were performed. The neoadjuvant chemotherapy regimen was used preoperatively in the experimental group to observe the clinical efficacy and compare adverse reactions and recurrence. Results The experimental group was treated effectively in 31 cases (88.6%) and in one year postoperatively in 2 cases (5.7%). The control group was treated effectively in 22 cases (62.9%) and postoperative recurrence in 8 cases (22.9%), the difference was statistically significant , P <0.05. Adverse reactions in both groups were 37.1% and 45.7%, respectively, with no significant difference (P> 0.05). Conclusion During the clinical treatment of gastric cancer patients, the effect of neoadjuvant chemotherapy before operation is significant, which is helpful to control tumor progression and reduce recurrence, which is worthy of clinical promotion.